Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles

A. Rodallec, C. Franco, S. Robert, G. Sicard, S. Giacometti, B. Lacarelle, F. Bouquet, A. Savina, R. Lacroix, F. Dignat-George, J. Ciccolini, P. Poncelet & R. Fanciullino

Developing targeted nanoparticles is a rising strategy to improve drug delivery in oncology. Antibodies are the most commonly used targeting agents. However, determination of their optimal number at the surface remains a challenging issue, mainly due to the difficulties in measuring precisely surface coating levels when prototyping nanoparticles. We developed an original quantitative assay to measure the exact number of coated antibodies per nanoparticle. Using flow cytometry optimized for submicron particle analysis and beads covered with known amounts of human IgG-kappa mimicking various amounts of antibodies, this new method was tested as part of the prototyping of docetaxel liposomes coated with trastuzumab against Her2+ breast cancer. This quantification method allowed to discriminate various batches of immunoliposomes depending on their trastuzumab density on nanoparticle surface (i.e., 330 (Immunoliposome-1), 480 (Immunoliposome-2) and 690 (Immunoliposome-3), p = 0.004, One-way ANOVA). Here we showed that optimal number of grafted antibodies on nanoparticles should be finely tuned and highest density of targeting agent is not necessarily associated with highest efficacy. Overall, this new method should help to better prototype third generation nanoparticles.
Cytometry (FCM) is one of the rare rapid, multi-parametric technologies that offers single particle analysis. This technique has already demonstrated its high interest in the characterization of both biological and synthetic particles. Interestingly, such FCM-based quantitative analysis of immuno-staining should be applied on an absolute rather than only relative basis through ad hoc calibration. This allows reproducible measurements at various time points providing more meaningful results expressed as molecules/cell rather than in arbitrary units (a.u.) of fluorescence. This “quantitative FCM” (QFCM) approach, allowing absolute quantification of membrane antigens, has already found several experimental or clinical applications. With the rise of biotherapies, such quantitative approach could be helpful in biopharmaceutical development both to measure the expression of target antigens and to characterize new entities.

Results

FCM method: development of a quantification assay for submicron particles. As described in detail in the Supplemental data section, the 10 µm QIFIkit calibrator, was scaled-down to generate a series of prototype 1 µm-sized “µ-QIFIkit” calibrator beads covering an approximate range of ~20 to ~20,000 mouse IgG/bead. The correlation coefficient r² of the prototype was equal to 0.9869 (Fig. 1A).

For further quantitation experiments on liposomes, a smaller series of 5 regularly spanned bead subsets were selected (Fig. 1B,C) to create a prototype “IgHk calibrator kit”, i.e.: 36-350-1,660-5,700-14,900 IgHk molecules/bead, considered equivalent to 18-175-830-2,850-7,450 human IgG molecules/bead, based on the theoretical expression of two kappa light chains per IgG. The correlation coefficient of this new IgHk prototype was 0.9993 (Fig. 1D).

Detection of immunoliposomes and quantification of coated trastuzumab on FCM. As explained in the method section, the triggering parameter for FCM analysis of liposomes was based on DiD fluorescence. The positivity threshold was defined using unstained immunoliposomes (Fig. 2A). Except from electronic and fluidic background, no DiD+ elements were detected. Using tagged liposomes, the SSC/DiD dot plot allowed the definition of the DiD (immuno)liposome gate. DiD bright elements were also excluded from the gate due to the possible generation of doublets or multiplets of immunoliposomes. DiD immunoliposomes were successfully detected (Fig. 2B). DiD+ Immunoliposome numeration provided using FCM represented 65% (see Supplemental data section for qNano: measurement of liposome concentration) of total Immunoliposomes counted using TRPS technology (qNano). Moreover, considering the PE quantification channel, the positivity threshold was adjusted using DiD+ uncoated liposomes incubated with the same anti-Human IgG-k PE MAb.
conjugate (Fig. 2C). This strategy allowed delineating the PE+/DID+ immunoliposome gate on a PE+/DiD+ dot plot (Fig. 2D). Finally, the Median Fluorescence intensity (MFI) of the pre-selected population was collected as arbitrary units of PE fluorescence and converted into the absolute number of kappa light chain/immunoliposome using our IgHk calibrator beads (Fig. 3). Based on the expression of two kappa light chains per IgG, we considered that immunoliposomes may theoretically bind 2 molecules of PE anti-Human IgG reagent (i.e., anti-human kappa light chain monoclonal antibody), resulting in dividing by 2 each result.

Thus, Immunoliposome-1, Immunoliposome-2 and Immunoliposome-3 exhibited 330 ± 30, 480 ± 110 and 690 ± 80 (p < 0.004, One-way ANOVA) coated trastuzumab per liposome, respectively.

**Immunoliposome characterization.** No significant difference in size, PDI and entrapment efficiency was observed between immunoliposome batches. According to DLS analysis, immunoliposome population was unimodal in size (i.e., PDI = 0.1 ± 0.01) with a mean diameter of 140 ± 3.4 nm. Docetaxel entrapment efficiency was >90%.

**Stability studies.** No significant difference in stability was observed between immunoliposome batches. As previously published, after 45 days, immunoliposome was steady, PDI increase was not significant (i.e., from 0.1 to 0.153 in 45 days) and mean docetaxel leakage was of 17 ± 13% per week. Evolution in time of coated trastuzumab is illustrated in Fig. 4. After an initial loss of maximum 20% in the first 2 weeks (i.e., 19% and 12%, p > 0.05, t-student) for Immunoliposome-1 and Immunoliposome-2, respectively, trastuzumab density remained stable for 45 days (p < 0.05, t-student). On the contrary, Immunoliposome-3 trastuzumab density presented strong variations with an apparent increase of 87% at day 45 (p = 0.011, One-way ANOVA).

**In vitro efficacy studies: bidimensional (2D) model.** Empty liposomes and trastuzumab alone did not show any apoptotic effect (data not shown). For all conditions, no significant difference (p > 0.05, One-way ANOVA) in apoptosis induction was observed between trastuzumab concentrations whether it was free or coated (Supplementary Figs. 2 and 3). For all treatment groups, induction of early apoptosis increased with time (p = 0.004, t-test) but no difference between them was observed (Table 1 and Fig. 5A). At 12 and 72 hours, when
treated with free docetaxel + trastuzumab, 12 ± 2% and 17 ± 6% of cells were in early apoptosis. Results were 11 ± 1% and 15 ± 5% when treated with liposome + free trastuzumab and 11 ± 1% and 16 ± 5% when treated with immunoliposomes (p = 0.427, One-way ANOVA and p = 0.917, One-way ANOVA, respectively). Similarly, induction of late apoptosis increased with time (p = 0.004, t-test) and no difference between treatment groups was observed either (Table 1 and Fig. 5B). At 12 and 72 hours, when treated with free docetaxel + trastuzumab, 23 ± 7%
and 50 ± 11% of cells were in late apoptosis. It was 19 ± 1% and 44 ± 8% when treated with liposome + free trastuzumab and 22 ± 5% and 38 ± 11% when treated with immunoliposomes (p = 0.551, One-way ANOVA and p = 0.298, One-way ANOVA, respectively).

In vitro efficacy studies: three-dimensional (3D) model. Empty liposomes and trastuzumab alone did not show cytotoxic effect on MDA-MB-453 (data not shown)26. Spheroid monitoring is summarized in Fig. 6. At day 14, cell viability was 80 ± 17, 57 ± 16, 41 ± 16, 31 ± 9 and 34 ± 19 when treated with free drugs, liposomes, Immunoliposome-1, Immunoliposome-2 and Immunoliposome-3, respectively (Fig. 7). Thus, immunoliposomes performed better than free drugs (p = 0.001, t-test) and liposomes (p = 0.045, t-test). However, no statistical difference was observed between the three immunoliposome batches (p > 0.05, One-way ANOVA).

Discussion
In the present study for the first time we used QFCM approach for characterizing third generation of drug-loaded liposomes, a.k.a. immunoliposomes. Here, we worked on prototyping docetaxel-trastuzumab immunoliposome which previously demonstrated in vitro and in vivo anti-tumor efficacy. However, two major hurdles had to be overcome: first, QFCM had never been applied yet on submicrometer-sized particles and second, FCM analysis of nanoparticles was still a major challenge27.

Schematically, two main QFCM strategies are still in use for absolute quantification of molecules on individual particles, using either direct (e.g., Quantibrite, BD Biosciences, San Jose, CA, USA) or indirect immuno-fluorescence (i.e., QIFIkit, Dako, Glostrup, D and CellQuant Calibrator, BioCytex, Marseille, France)13,16,17. A third new, more specific and possibly more robust approach, is to create calibrator beads directly coated with the antigen of interest in various known amounts28. Such calibrator beads can be tailored to the appropriate size and antigen density range to mimic the particles of interest in the effective staining protocol. This was our present strategy, with kappa light chains of human IgG (so-called “IgHk”) as the target antigen mimicking trastuzumab molecules coated on immunoliposomes. Using transitional calibration systems, we progressively reduced beads size and antigen density from 10 µm to 1 µm and from a few dozens to a few thousands’ molecules/bead, respectively, leading us to select a set of 5 calibrator beads, so-called "IgHk calibrator beads", exhibiting from 36 to 14900 IgHk molecules/bead.

However, a few special technological tricks still had to be developed to achieve our final goals: first, fluorescence tagging to sort-out liposomes from non-specific events (i.e., both electronical and optical background) and second, the best sensitivity as possible in terms of fluorescent detection.

Indeed, because of their low refractive index and detection as compared to polystyrene beads of similar size range, liposomes generate very faint scatter signals. To overcome this major limitation, we followed other specialists’ suggestion to use a fluorescence-based rather than a scatter-based triggering parameter29–31. Thus, immunoliposomes were labeled during synthesis using a lipophilic fluorescent dye (i.e. DiD) with a different color than the reporting immunological reagents. As a result, immunoliposomes were defined as dye positive, green fluorescent particles on which human IgG should be quantified.

Then, to benefit from the highest sensitivity and allow a clear resolution, using last generation cytometer Cytoflex S (Beckman-Coulter, Villepinte France) we excited phycoerythrin (PE), one of the brightest fluorochrome available, at its optimal absorption peak (i.e. 561 nm instead of 488 nm for several benchtop instruments).

Together these two tricks allowed us to detect 65% of immunoliposome population and to consider this FCM analysis as representative of all immunoliposomes.

Thus, this QFCM method provides the effective number of IgG per particle on an absolute, rather than relative, basis and allows independent measurements along time. This may be quite useful for initial and long-term quality control of the MAb coating, as illustrated here in our 6 weeks long stability study. Associated with other absolute size measurement techniques such as DLS, it may also allow calculation of true surface density, expressed
as molecules per surface unit, which may become useful for comparison of immunoliposomes with different sizes when several prototypes have to be tested.

To our knowledge, this is the first description of a FCM-based quantitative analysis of antigens/receptors on submicron particles and can be easily adapted to any other target molecule that could be biotinylated. Noteworthy, QFCM can not only provide a median value for the number of molecules per particle but can also inform about the dispersion of the immunoliposome contains, as it was illustrated in Fig. 3. Thus, both median density and homogeneity of coating comes at hands, even on very small particles such as liposomes.

Finally, this new method was used to evaluate the influence of median trastuzumab density on the cytotoxic effect of immunoliposomes. To test our hypothesis, three different batches of immunoliposomes were synthesized and exhibited a 330–690 range of coated trastuzumab per liposome, respectively. As previously published, Immunoliposomes displayed a steady size but mild docetaxel leakage over time. Similarly, for Immunoliposome-1 and Immunoliposome-2, coated trastuzumab slightly decreased weekly. Oppositely, coated trastuzumab on Immunliposome-3 seemed to increase over time (i.e., +190% after 45 days) raising numerous questions. It is likely that this increase in coating was related to immunoliposome DiD staining. Indeed, DiD staining is a key point in our quantification technique since only fluorescent immunoliposomes can be accurately analyzed on Cytoflex S (Fig. 2). However, as docetaxel, DiD is a lipophilic agent and is expected to leak from liposome bilayers over time. Thus, the smaller liposomes which are considered less stable loose rapidly their fluorescence and become invisible within a few weeks to CMF analysis. Since smaller liposomes are expected to exhibit lower number of coated trastuzumab, this loss in DiD staining could be responsible for an analysis of larger liposomes only, after a few weeks, thus resulting in increased coated trastuzumab density. Although it appeared as a limitation of our new quantification assay when applied to stored liposomes, it could be overcome using extemporaneously-synthesized liposomes or steadier nanoparticles such as inorganic or polymeric ones.

The three batches of immunoliposomes were then tested in vitro on bidimensional (2D) and three-dimensional (3D) models. We found that similarly to standard MTT assays, apoptosis studies using 2D models were not suitable to discriminate the efficacy of the various immunoliposomes as compared with free docetaxel or liposomal docetaxel. Conversely when using 3D spheroids, we found that all immunoliposomes performed better than free docetaxel and its liposomal form. Although not significant, differences between Immunoliposome batches were observed because higher antiproliferative efficacy was achieved with Immunoliposome-2 and Immunoliposome-3 as compared with Immunoliposome-1. Reducing the coating probably led to a loss in cellular

Figure 6. Monitoring of dtomato fluorescent MDA-MB-453 when seeded in 4000 cell spheroids and treated at day 3 and day 10. *Experiment was in triplicate.

Figure 7. Cell viability (%) of MDA-MB-453 spheroids 14 days after seeding. *Values are mean of three or more experiments.
Table 2. Successive steps involved for the calibration and application of the prototype “IgH\(\kappa\) calibrator beads”.

| Calibrator beads | QIFIkit (commercial) | Mini-QIFIkit (prototype) | mini-QIFIkit (prototype) | \(\mu\)-QIFIkit (prototype) | “IgH\(\kappa\) beads” (prototype) | “IgH\(\kappa\) beads” (prototype) |
|------------------|--------------------|-------------------------|-------------------------|---------------------------|---------------------------------|---------------------------------|
| Diameter         | 10 µm              | 3 µm                    | 3 µm                    | 1 µm                      | 1 µm                           | 1 µm                            |
| Coated analyte   | Mouse IgG          | Biotin-IgG (mouse)      | Biotin-IgG (mouse)      | Biotin-IgG (mouse)        | REAfinity® CD151:biotin (human IgG-k) | Trastuzumab-on liposomes (human IgG-k) |
| Coating method   | Proprietary        | Magnetic SA-beads       | Magnetic SA-beads       | Magnetic SA-beads         | Magnetic SA-beads               | Covalent coupling                |
| Calibration FCM  | instrument         |                         |                         |                           |                                |                                 |
| Staining method  | QIFI (indirect IF  | QIFI (indirect IF with  | QIFI (indirect IF with  | QIFI (indirect IF with  | QIFI (indirect IF with  | Direct IF with L1C1-PE (anti-human kappa) |
| Laser height at  | or > 10 µm,       | unlabeled mouse IgGs)   | unlabeled mouse IgGs)   | unlabeled mouse IgGs)     | unlabeled mouse IgGs)          |                                 |
| interrogation point | (depending on instrument) | | | | | |
| Excitation λ     | 488 nm             | 488 nm                  | 561 nm                  | 561 nm                    | 561 nm                         | 561 nm                          |
| Calibration channel | FITC              | FITC                    | PE                      | PE                        | PE                             |                                 |
| Calibration curve(s) | N.A.             | Fig. S1a                | Fig. S1b                | Fig. S1c                  | Fig. 1                         | Fig. 2                          |

up take, thus impairing trastuzumab and docetaxel cytotoxic effects. Conversely, increasing, trastuzumab coating proved to be at best equally effective but not better, and was then nothing but a waste in trastuzumab during synthesis. Indeed, although 45% more molecules of trastuzumab were coated on Immunoliposome-3, it resulted in similar cellular uptake and antiproliferative efficacy, possibly because of steric hindrance and binding-site barrier issues. Thus, Immunoliposome-2, corresponding to 480 ± 110 molecules of coated trastuzumab per liposome, could be the optimal number of trastuzumab to be coated to ensure a maximal efficacy in this breast cancer model. Interestingly, preliminary in vitro efficacy studies have already shown its benefit over free docetaxel + free trastuzumab and antibody drug conjugate T-DM1.

Although, the present technology-oriented study needs more investigations, for instance about cell Her2 expression influence, our data already suggest that maximal density of the targeting agent is not a major requirement for achieving maximal sensitivity, thus highlighting how bio-physical parameters must be finely tuned and how critical is the need for an accurate quantification of the targeting agent on NP’s surface. Confirmation on more sophisticated in vitro and in vivo models may also be of major interest to better illustrate the exquisite specificity of immunoliposome-based treatments.

Outlook. For the first time, we have developed a sensitive FCM-based quantitative method to measure the number of coated antibodies on nanoparticles. This new quantification assay can help to characterize targeting nanoparticles as part of early prototyping steps. In addition, it can also be used as a quality control tool to control batch-to-batch variations when the optimal NP has been selected. Applied to docetaxel – trastuzumab immunoliposomes in a model of Her2+ breast cancer cell line, FQFCM was successfully used to precise the optimal number of trastuzumab molecules to coat to achieve a maximal efficacy. Beyond this first application, we believe that this original method could be useful to researchers looking for a rapid, simple and precise method to quantify any monoclonal antibodies used as targeting agents when developing smart nanoparticles.

Methods

Drugs and chemicals. Egg yolk phosphatidylcholine (PC), phosphatidylglycerol (PG), cholesterol (Chol), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (PEG) and Paclitaxel were purchased from Sigma (St Quentin-Fallavier, France). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N\-(maleimide(polyethylene glycol))-2000 (Mal-PEG) were purchased from Coger (Paris, France). Docetaxel was purchased from WVR (Fontenay sous bois, France) and DiD fluorescent tag from Thermo Fisher (Illkirch, France). Trastuzumab (Herceptin) was kindly given by Genentech (South San Francisco, CA, USA). Anti-human IgG PE (clone L1C1) and a prototyped human IgG kappa light chains quantification kit for submicron particles (e.g., immunoliposomes) were provided by Biocytex (Marseille, France) as described below. All other reagents were of analytical grade.

FQFCM method: development of a quantification assay for human IgG on submicron particles. For FQFCM analysis of submicron particles both the size and measuring range of the official calibration systems (i.e., 10 µm diameter and 3,300 to 783,000 IgG/bead for QIFIkit, DAKO, Glostrup, Denmark) are far too high for the specific needs. Thus, we had to reduce both parameters towards the more acceptable diameter of 1 µm and range of a few dozens to a few thousands’ molecules/bead. This was done in successive steps as summarized in Table 2 and detailed in the Supplemental data section depicting the generation of the prototype “\(\mu\)-QIFIkit” calibrator.

To generate “IgH\(\kappa\) calibrator beads”, 1 µm magnetic beads coated with streptavidin (MyOne-SYNabeads, Dynal-InVitrogen) were decorated with increasing amounts of a human IgG kappa (IgG\(\kappa\)) Mab (REAfinity® CD151:biotin, Mylenyi-Biotech France), used to mimic and calibrate trastuzumab molecules present on immunoliposomes. After an incubation of 2 min, the beads were washed using a magnet (Dynal mini-MPC), suspended in PBS-BA binding buffer (PBS-0.1% BSA-0.1% NaNa3) to a concentration of 80*10^6 µS/mL (2.5*10^5/ test) and stored at 2–8 °C. Their calibration was operated by the QIFI assay (Quantitative Immuno-Fluorescence...
Indirect assay) as described in the QIFIkit box insert but using the 1µm-sized µ-QIFIkit beads as reference (see Supplemental data section for µ-QIFIkit generation) after 1st step saturation with the anti-human kappa light chain L1C1 Mab, intermediate washing with the magnet and fluorescent staining with a PE-conjugated anti-mouse IgG (H + L) polyclonal antibody as 2nd step reagent (Jackson ImmunoResearch, d = 100). Beads covering the appropriate range of IgHk were then selected for QFCM analysis of immunoliposomes.

Since liposomes (submicron particles in general) are inappropriate to afford washing steps, a direct IF no-wash protocol was then adapted for their staining. L1C1 anti-IgHk Mab was directly conjugated to PE and purified according to BioCytex internal procedures. Titration was done in the final assay with high concentration of the highest level IgHk-expressing beads to ensure saturating conditions without excess of PE-Mab. With this Mab of rather high affinity, the saturating PE-conjugate initial concentration during staining was not more than 5 µg/mL and thus less than 2 µg/mL in the final diluted suspension during QFCM analysis.

**Immunoliposome preparation.** As previously described, liposomes were synthesized using the Thin-Film method. PC, Chol, PG, docetaxel and Mal-PEG were mixed in a 50:19:15:1.7:1 molar ratio. Briefly, lipids were dissolved in methanol. Lipid solution was further mixed with DiD as lipophilic membrane insertable fluorescent reporter when required for liposome-oriented FCM analysis. Methanol was then removed by rotary evaporation (Laborota 4003, Heidelberg Instruments, Schwabach, Germany) at 38 °C. After 30 minutes a thin lipid film was obtained. To remove the remaining solvent, this lipid film was dried under a stream of nitrogen for two hours at room temperature. The film was then hydrated with a 5% vol/vol glucose solution and large liposomes were obtained. Reduction and homogenization in size was thus achieved by two cycles of extrusion through 100 nm and 80 nm polycarbonate pore membranes (Nucleopore, Whatman) using a LipoFast LF-50 extruder. Trastuzumab was then coated using a maleimide linker, requiring a preliminary step of trastuzumab thiolation. Trastuzumab was first dissolved in a 0.1 M sodium phosphate buffer (PBS) pH 8.0 containing 5 mM EDTA and mixed under constant shaking, for two hours at room temperature with a Traut’s reagent solution at 1:10 molar ratio (Traut’s:trastuzumab). Thiocatalyzed trastuzumab was then directly mixed with the pegylated liposomes at 1:508 (Immunoliposome-1), 1:127 (Immunoliposome-2) and 1:16 (Immunoliposome-3) trastuzumab:Mal-PEG molar ratio. The mixture was kept under constant shaking at 4 °C overnight. Unbound trastuzumab and free docetaxel were removed using 6,000 g centrifugation on MWCO 300KDa Vivaspins (VWR,Fontenay sous bois, France) followed by size exclusion chromatography on qEV columns (IZON Science, Lyon, France).

**Size and polydispersity study.** Size and polydispersity index (PDI) were measured by Dynamic light scattering (DLS). Liposomes and immunoliposomes were diluted in a PBS solution and then analyzed by a Zeta sizer Nano S (Malvern instruments, UK). Liposomal preparations were considered unimodal for a PDI < 0.247.

**Docetaxel entrapment efficiency.** Docetaxel concentrations were measured using a validated HPLC-UV method after liquid/liquid extraction using a C18 column (25 cm × 4.6 mm, 5 µm). The mobile phase was composed of 53% of ammonium acetate buffer (35 mM, pH 5) and 47% of acetonitrile. Samples were eluted at a constant flow rate of 1.8 ml/min with UV detection (227 nm). Data were acquired and analyzed using Chemstation software (Agilent, France). Docetaxel and paclitaxel typical retention times were respectively 11 minutes and 370.247 minutes. Docetaxel entrapment efficiency was calculated using the following formula:

\[
\text{Entrapment efficiency} = \frac{(\text{mg DOCE HPLC measured})}{(\text{mg DOCE present before centrifugation})} \times 100.
\]

**Flow cytometric detection and quantitative analysis of trastuzumab-coated Immunoliposomes.** QFCM analysis was performed on highly sensitive flow cytometer, CytoFLEX S (Beckman-Coulter, Villepinte, France) using PE-conjugated polyclonal or monoclonal antibodies and 561 nm excitation laser.

To avoid unspecific events mixing with liposomes in the FCM analysis, fluorescent triggering was involved, using a generic red fluorescent signal issued from the red laser excitation point, totally independent from the PE-Mab staining which provides orange fluorescence from the yellow laser. To apply such a generic staining, liposomes were tagged with DiD fluorescent lipophilic molecules, which encapsulated in the phospholipid bilayer of all liposomes. Consequently, the triggering parameter for their analysis on the CytoFLEX S was the red fluorescence of DiD taken from the red laser.

To determine the percentage of immunoliposome detected with flow cytometry, an absolute quantification of immunoliposomes was performed using TRPS technology (qNano, IZON, Lyon France).

**Stability studies.** Stability studies were performed in PBS at 4 °C, protected from light. Immunoliposome size, PDI, docetaxel leakage and persistence of coated trastuzumab were evaluated weekly for a month, then bimonthly for up to 45 days, using differential centrifugation to separate NPs from soluble material.

**Cell lines.** In vitro experiments were carried on HER2+ human breast cancer cell line MDA-MB-453. Cells were purchased from the American Type Culture Cell (Molsheim, France) cultured in RPMI (Thermo Fisher, Illkirch, France) supplemented with 10% FBS, 1% penicillin and 0.16% kanamycin and grown in a humidified CO2 incubator at 37 °C. Cells were regularly checked for cell viability, morphology and doubling time. Cells were stably transfected with dTomato lentivirus developed and kindly provided by Pr Jacques Robert (Institut Bergonié, Bordeaux, France) and selected with blasticidin to allow fluorescence imaging.
In vitro efficacy studies: 2D model. To evaluate cell apoptosis, we used flow cytometry with an Annexin V/PI kit (Sigma Aldrich, St Quentin Fallavier, France). MDA-MB-453 were seeded at a density of $7 \times 10^5$ cells per well in 6-well plates. After overnight attachment, cells were exposed to free docetaxel + free trastuzumab (i.e., free drugs), docetaxel liposomes + free trastuzumab (i.e., Liposome), and Immunoliposome-1, Immunoliposome-2 and Immunoliposome-3. Treatments were incubated 3 days after seeding. Cells were exposed continuously to treatments for a week, then treatment was repeated, and drugs incubated until day 14. For all conditions concentration of docetaxel was 8 nM. Cell viability was determined using CellTiter-Glo (Promega, Charbonnières-les-Bains), following manufacturer’s guidelines and luminescent spectrophotometric reading on PHERAsyst FSX (BMG Labtech, Heathfield, UK). Spheroids were also monitored daily using a fluorescence microscope (Nikon, Eclipse TS100), coupled to digital camera.

Statistical analysis. Similarly to all our studies\textsuperscript{26,27}, in vitro experiments were performed at least in triplicate and data were represented as mean ± standard deviation (SD) or ± standard error of the mean (SEM). Statistical analyses were performed on SigmaStat (San Jose, USA). Differences between treatments were analyzed by One-Way Anova with Multiple Comparison testing or Student’s $t$-test according to data distribution and sample size.

Received: 30 September 2019; Accepted: 6 February 2020; Published online: 05 March 2020

References

1. Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998).
2. Rodallec, A., Benzekry, S., Lacarelle, B., Ciccolini, J. & Fanciullino, R. Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology. Critical Reviews in Oncology/Hematology 129, 1–12 (2018).
3. Fanciullino, R. et al. Biodistribution, Tumor Uptake and Efficacy of 5-FU-Loaded Liposomes: Why Size Matters. Pharm Res 31, 2677–2684 (2014).
4. Farokhzad, O. C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103, 6315–6320 (2006).
5. Gu, F. X. et al. Targeted nanoparticles for cancer therapy. Nano Today 2, 14–21 (2007).
6. Cheng, J. et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869–876 (2007).
7. Rodallec, A. et al. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. Int J Nanomedicine 13, 3451–3465 (2018).
8. Yang, T. et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. Journal of Controlled Release 120, 169–177 (2007).
9. Zhou, Z., Badkas, A., Stevenson, M., Lee, J.-Y. & Leung, Y.-K. Herceptin conjugated PLGA-PHiE-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. International Journal of Pharmaceutics 487, 81–90 (2015).
10. Choi, W. I. et al. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab. Nanomedicine: Nanotechnology, Biology and Medicine 11, 359–368 (2015).
11. Dhautcourt, J.-L. Quantitative flow cytometric analysis of membrane antigen expression. Curr Protoc Cytom Chapter 6, Unit 6.12 (2002).
12. Poncelet, P. et al. Tips and tricks for flow cytometry-based analysis and counting of microparticles. Transfus. Apher. Sci. 53, 110–126 (2015).
13. Poncelet, P. & Carayon, P. Cytosfluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J. Immunol. Methods 85, 65–74 (1985).
14. Poncelet, P., George, F., Papa, S. & Lanza, F. Quantitation of hemopoietic cell antigens in flow cytometry. Eur J Histochem 40(Suppl 1), 15–32 (1996).
15. Poncelet, P. Microbeads and flow cytometry: how and why put the ‘-metry’ in immuno-cytometry? vol. 62 (2004).
16. Gratama, J. W. et al. Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis. Cytometry 33, 166–178 (1998).
17. Serke, S., Lessen, A. & Huhn, D. Quantitative fluorescence flow cytometry: A comparison of the three techniques for direct and indirect immunofluorescence. Cytometry 33, 179–187 (1998).
18. Schwartz, A., Marti, G. E., Poon, R., Gratama, J. W. & Fernandez-Ropellet, E. Standardizing flow cytometry: a classification system of fluorescent standards used for flow cytometry. Cytometry 33, 106–114 (1998).
19. Bikoue, A. et al. Quantitative analysis of leukocyte membrane antigen expression: normal adult values. Cytometry 26, 137–147 (1996).
20. Stewart, J. J. et al. Role of receptor occupancy assays by flow cytometry in drug development. Cytometry B Clin Cytom 90, 110–116 (2016).
21. Green, C. L. et al. Recommendations for the development and validation of flow cytometry-based receptor occupancy assays. Cytometry B Clin Cytom 90, 141–149 (2016).
48. Garg, M. B. & Ackland, S. P. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. Invest New Drugs 30, 1121–1131 (2012).

22. Mouland, M. & Oxtoux, M.-L. How validated receptor occupancy flow cytometry assays can impact decisions and support drug development. Cytometry B Clin Cytom. 90, 150–158 (2016).

23. Lapusan, S. et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30, 1121–1131 (2012).

24. Engelberts, P. J. et al. A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and olatumumab. J. Immunol. Methods 388, 8–17 (2013).

25. Rodallec, A. et al. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. International Journal of Nanomedicine, https://www.dovepress.com/docetaxel-trastuzumab-stealth-immunoliposome-development-and-in-vitro-peer-reviewed-article-IJN https://doi.org/10.2147/IJN.S162454 (2018).

26. Rodallec, A. et al. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. Int J Nanomedicine 13, 6677–6688 (2018).

27. Ginte, S. et al. Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. J. Thromb. Haemost. 15, 187–193 (2017).

28. Schuster, H. et al. The immunopeptidomic landscape of ovarian carcinomas. Proc. Natl. Acad. Sci. USA 114, E9942–E9951 (2017).

29. Arnaud, N., Gounou, C., Turpin, D. & Brisson, A. R. Fluorescence triggering: A general strategy for enumerating and phenotyping extracellular vesicles by flow cytometry. Cytometry A 89, 184–195 (2016).

30. Stener, S. A. et al. High sensitivity flow cytometry of membrane vesicles. Cytometry A 89, 196–206 (2016).

31. Libregts, N. F. W. M., Arkesteijn, G. J. A., Németh, A., Nolte-‘t Hoen, E. N. M. & Wauben, M. H. M. Flow cytometric analysis of extracellular vesicle subsets in plasma: impact of swarm by particles of non-interest. J. Thromb. Haemost. 16, 1423–1436 (2018).

32. Kovira-Bru, M., Thompson, D. H. & Szélefi, I. Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures. Biophys. J. 83, 2419–2439 (2002).

33. Sabat, J., Prieto, G., Roso, J. M., Hidalgo-Álvarez, R. & Sarmiento, F. Size and stability of liposomes: A possible role of hydration and osmotic forces. Eur. Phys. J. C 20, 401–408 (2006).

34. Sambale, F. et al. Three dimensional spheroid culture for nanoparticle safety testing. Journal of Biotechnology 205, 120–129 (2015).

35. Li, Y., Kröger, M. & Liu, W. K. Endocytosis of PEGylated nanoparticles accompanied by structural and free energy changes of the grafted polyethylene glycol. Biomaterials 35, 8467–8478 (2014).

36. Ho-Pun-Cheung, A. et al. Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer. PLoS One 7 (2012).

37. Gabori, N. et al. Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J. Biol. Chem. 286, 11337–11345 (2011).

38. Costa, E. C., Gaspar, V. M., Marques, J. G., Coutinho, P. & Correia, I. J. Evaluation of Nanoparticle Uptake in Co-culture Cancer Cell Lines Using the Dako QIFIKIT. Cytometry A 19, 209–217 (1994).

39. Olejniczak, S. H., Stewart, C. C., Donohue, K. & Czuczman, M. S. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol. Invest. 35, 93–114 (2006).

40. Poncelet, P. et al. Clinical applications of quantitative immunophenotyping. In: Stewart, C. C. & Nicholson, J. A. eds. Immunophenotyping, New-York: Wiley-Liss, 2000: 105–32 (Springer, New York, NY, 1986).

41. Battle, R. & Clark, B. Quantitative analysis of human leucocyte antigen expression during culture of Epstein-Barr virus-transformed cell lines using the dako QIFIKIT. Br. J. Biomed. Sci. 64, 32–34 (2007).

42. Poncelet, P., Franco, C. & Ruf, W. Immunological calibration of fluorescence scales for microvesicle analysis by flow cytometry. Abst. # 209, CYTO 2017, 32nd Congress of the International Society for Advancement of Cytometry, June 10–14, Boston (MA) (2017).

43. Poncelet, P. Microbeads and flow cytometry: how and why put the ‘metry’ in immuno-cytometry! Annales de biologie clinique, 62, 427–435 (2015).

44. Garg, M. B. & Ackland, S. P. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J. Chromatogr. B Biomed. Sci. Appl. 748, 383–388 (2000).

Acknowledgements
The authors would like to thank the Ligue Nationale Contre le Cancer who generously provided a grant to AR and the platform Amuticyt (VRCM) de la faculté de Pharmacie La Timone for their technical expertise. This study was partly supported by the French Institut Roche and Genentech which kindly provided trastuzumab.

Author contributions
A.R., G.S., R.F., J.C., S.R., C.F. and S.G. performed the bench experiments. A.R., R.F. and J.C. performed statistical analyses. A.R., R.F., A.S., F.B., S.R., F.D.G., C.F., P.P., B.L., R.L. and J.C. wrote the manuscript. All authors contributed toward data analysis, drafting and revising the paper, and agree to be accountable for all aspects of the work.

Competing interests
A.S. and F.B. are members of Institut Roche, a joint institute from Roche Laboratories that commercializes trastuzumab and has partly funded this study. J.C. and R.F. obtained fees as board members of Roche. C.F. and P.P. are members of Biocytex that developed the prototype IgHg calibration beads. The other authors report no conflicts of interest in this work.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-60856-z.

Correspondence and requests for materials should be addressed to R.F.
